Welcome to the 5th RNA Editing Summit 2024
Pioneering RNA Editing Drugs Towards Clinical Realities
Despite remarkable advancements, such as Wave Life Sciences pioneering the first clinical candidate and significant investments like Ascidian Therapeutics securing $40 million for their RNA editing pipeline, challenges persist in optimizing delivery and ensuring treatment longevity for new RNA editing therapies.
Ran inJune 2024, the 5th RNA Editing Summit addressed these obstacles head-on. Our updated agenda featured fresh content and an enhanced pre-conference focus day, spotlighting brand-new advances towards the clinic and strategies for targeting beyond the liver.
We joined leading companies like Wave Life Sciences, ProQR Therapeutics, Korro Bio, Shape Therapeutics, EdiGene, and more as we convened industry experts and thought leaders. With over 80 technical and strategic minds coming together, this summit delivered data-driven presentations and interactive discussions which propelled RNA editing therapeutics through the clinic and toward regulatory approval.
What Did You Miss in 2024?
Clinical Program Update
Hear about the first-ever RNA Editing clinical program from Wave Life Sciences, helping you and your team accelerate your RNA editing therapeutics through the clinic and increase your chance of success
Brand New Focus Day
Overcome targeted delivery as one of the main challenges holding back RNA editing from becoming clinical reality with a full day of data- and discussion- led delivery content to increase durability, potency and specificity of your RNA editing drugs
Fresh Insights and Brand-New Data:
With 80% brand new speaker faculty from new companies such AIRNA, Amber Bio, Jorna Therapeutics, Radar Therapeutics and Splice Therapeutics, access innovative strategies including, but not limited to, machine learning, screening tools, ADAR, RNA trans splicing, and splice switching to unlock RNA editing broad therapeutic potentials by addressing what were previously undruggable targets
2024 Expert Speakers:
2024 Partners:
Who Attends this Meeting?
